Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Rhea-AI Summary
Trevi Therapeutics (Nasdaq: TRVI) will present an oral presentation and multiple posters at the American Thoracic Society (ATS) 2026 International Conference, May 15–20, 2026, Orlando. Key items include Phase 2b CORAL primary and subgroup analyses, Phase 2a RIVER exploratory results, and Phase 1 drug–drug interaction data with pirfenidone and nintedanib.
Oral presentation: CORAL Phase 2b primary and subgroup analyses on May 18, 2:27–2:39 p.m. ET. Multiple poster sessions scheduled May 17–19 with presenters and session details listed.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TRVI
On the day this news was published, TRVI gained 0.80%, reflecting a mild positive market reaction. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $1.78B at that time.
Data tracked by StockTitan Argus on the day of publication.
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use
An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough
Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib
NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it will deliver an oral presentation and present multiple abstracts at the American Thoracic Society (ATS) 2026 International Conference, taking place from May 15 – 20, 2026, in Orlando, Florida.
Oral Presentation
Abstract: A Phase 2b Trial (CORAL) of Nalbuphine Extended-release Tablets in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough: Primary and Subgroup Analyses
Oral Presentation Session: B95 Fibrosis, Cough, and Inflammation: Treatment Strategies in ILD
Date & Time: May 18, 2:27 p.m. to 2:39 p.m. ET
Location: W304 E-H (Level III, OCCC West Concourse)
Presenter: Philip L. Molyneaux, MD, PhD
Poster Presentations
Abstract: Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release with Pirfenidone or Nintedanib: A Phase 1 Drug-Drug Interaction Study
Poster Session: A75 Late Breaking Abstracts in Clinical Problems
Date & Time: May 17, 11:30 a.m. to 1:15 p.m. ET
Location: Area L, Halls WA2-WA3 (Level I, OCCC West Concourse)
Presenter: James Cassella, PhD
Abstract: The Effect of Nalbuphine Extended Release on Cough Bouts in Patients with Idiopathic Pulmonary Fibrosis from a Phase 2b Randomized Clinical Trial (CORAL)
Poster Session: A110 Closing the Gap: Advances in Pulmonary Fibrosis
Date & Time: May 17, 2:15 p.m. to 4:15 p.m. ET
Location: West F3 (Level II, OCCC West Concourse)
Presenter: Jaclyn Smith, PhD, MBChB
Abstract: Nalbuphine Extended Release Reduces Cough Bouts in Patients with Refractory Chronic Cough in the Phase 2a RIVER Trial
Poster Session: B29 The Latest in Airway Symptoms and Disease
Date & Time: May 18, 9:15 a.m. to 11:15 a.m. ET
Location: W414AB (Level IV, OCCC West Concourse)
Presenter: Jaclyn Smith, PhD, MBChB
Abstract: Evaluating the Burden of Chronic Cough in Patients with Interstitial Lung Disease: A US Survey-based Analysis of Its Effects on Daily Life and Emotional and Social Well-being
Poster Session: B39 Breath and Burden: Diffuse Lung Diseases and Daily Life
Date & Time: May 18, 11:30 a.m. to 1:15 p.m. ET
Location: Area A, Halls WA2-WA3 (Level II, OCCC West Concourse)
Presenter: Jeffrey J. Swigris, DO, MS
Abstract: The Effect of Nalbuphine Extended-Release Tablets on Breathlessness in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough from the Phase 2b CORAL Trial
Poster Session: C103 The Next Frontier of Therapy in Pulmonary Fibrosis
Date & Time: May 19, 2:15 p.m. to 4:15 p.m. ET
Location: West F3 (Level II, OCCC West Concourse)
Presenter: Donald A. Mahler, MD
Final results from the presentations listed above will be presented at the ATS International Conference; Registration Details
About the Phase 2b CORAL Trial
The Phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of nalbuphine ER (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF chronic cough were randomized 1:1:1:1 to one of three nalbuphine ER dose groups or placebo with an initial 2-week titration period to the target dose followed by 4 weeks of fixed dosing. The primary efficacy endpoint for the trial was the relative change in 24-hour cough frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for nalbuphine ER compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug or placebo.
About the Phase 2a RIVER Trial
The Phase 2a Refractory Chronic Cough Improvement Via Nalbuphine ER (RIVER) trial was a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, and tolerability of nalbuphine ER for the treatment of patients with RCC. Each treatment period lasted 21 days, separated by a 21-day washout period. During the nalbuphine ER treatment period, patients were titrated with assessments at 27 mg twice daily (BID), 54 mg BID, and 108 mg BID for objective cough and other assessments at each dose. The primary endpoint of the trial was the mean change in 24-hour cough frequency, as determined by an objective cough monitor, for the full analysis set (FAS) population at Day 21. The FAS population included all patients who received at least one dose of study drug and have objective cough count data on both Baseline and Day 21 in at least one treatment period.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
